MPLT Stock Summary and Trading Ideas (Maplight Therapeutics | NASDAQ:MPLT)

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Maplight Therapeutics trades on the NASDAQ stock market under the symbol MPLT.

As of November 9, 2026, MPLT stock price climbed to $7.28 with 438,971 million shares trading.

MPLT has a beta of 0.69, meaning it tends to be less sensitive to market movements. MPLT has a correlation of 0.00 to the broad based SPY ETF.

MPLT has a market cap of $404.59 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that MPLT belongs to (by Net Assets): IWM, VXF, VTI, VTWO, IWO.

MPLT has underperformed the market in the last year with a price return of -54.9% while the SPY ETF gained +13.4%. MPLT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -45.2% and -8.7%, respectively, while the SPY returned -1.8% and -1.0%, respectively.

MPLT support price is $6.53 and resistance is $7.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MPLT shares will trade within this expected range on the day.